期刊文献+

替加环素致胆红素水平升高 被引量:4

Elevation of serum bilirubin level due to tigecycline
原文传递
导出
摘要 1例74岁男性患者因小肠憩室伴穿孔术后发生感染性休克,静脉滴注替加环素50 mg/12 h。用药前TBil 11.1 μmol/L,DBil 2.3 μmol/L,间接胆红素(IBil) 8.2 μmol/L。用药第4天,患者TBil 99.1 μmol/L,DBil 48.1 μmol/L,IBil 32.3 μmol/L;第6天,患者皮肤出现黄染,TBil 206.3 μmol/L,DBil 126.7 μmol/L,IBil 45.4 μmol/L。停用替加环素。停药后第4天,患者TBil 167.4 μmol/L,DBil 98.2 μmol/L,IBil 36.1μmol/L。2周后电话随访,患者TBil 18.3 μmol/L,DBil 3.4 μmol/L,IBil 11.6 μmol/L。 A 74 year old male patient received an IV infusion of tigecycline 50 mg per 12 hours because of septic shock induced by diverticulum of small intestine complicated with perforation after surgery. Before IV infusion, the results of laboratory test showed the following valumes: total bilirubin (TBil) 11.1 μmol/L, direct bilirubin (DBil) 2.3 μmol/L, indirect bilirubin (IBil) 8.2 μmol/L. On day 4 of drug administration, the results of laboratory test showed the following volumes: TBil 99.1 μmol/L, DBil 48.1 μmol/L, IBil 32.3 μmol/L. On day 6 of drug administration, the patient developed yellow scle, the results of laboratory test showed the following volumes: TBil 206.3 μmol/L, DBil 126.7 μmol/L, IBil 45.4 μmol/L. Tigecycline was stopped. On day 4 of drug withdrawal, the results of laboratory test were TBil 167.4 μmol/L, DBil 98.2 μmol/L, IBil 36.1μmol/L. Two weeks later, TBil was 18.3μmol/L, DBil 3.4 μmol/L, IBil 11.6μmol/L.
作者 李双
出处 《药物不良反应杂志》 CSCD 2016年第6期464-465,共2页 Adverse Drug Reactions Journal
关键词 胆红素 替加环素 Bilirubin Tigecycline
  • 相关文献

参考文献4

二级参考文献36

  • 1厉有名.药物性肝损害的临床类型及诊断策略[J].中华肝脏病杂志,2004,12(7):445-446. 被引量:252
  • 2许建明.急性药物性肝损伤诊治建议(草案)[J].中华消化杂志,2007,27(11):765-767. 被引量:348
  • 3U.S. Food and Drug Administration. FDA Drug Safety Communi-cation : FDA warns of increased risk of death with IV antibacterialTygacil ( tigecycline ) and approves new Boxed Warning [ EB/OL]. ?2013-10-01 ) [2015-01-10]. http://www.fda.gov/Drugs/DrugSafety/ucm369580. htm.
  • 4U.S. Food and drug Administration. FDA Drug Safety Communi-cation :Increased risk of death with Tygacil ( tigecycline )compared to other antibiotics used to treat similar infections [ EB/OL]. ( 2014-08-14 ) [2015-01-10]. http://www. fda. gov/Drugs/DrugSafety/ucm224370. htm.
  • 5Noskin GA.Tigecycline : a new glycylcycline for treatment ofserious infections[J].Clin Infect Dis,2005,41(suppl 5):S303-314.
  • 6Gilson M,Moachon L,Jeanne L,et al.Acute pancreatitis re-lated to tigecycline: case report and review of the literature[Jl.Scand J Infect Dis,2008,40(8):681-683.
  • 7Emmanuel 0,Christian E,Robbert van M,et al.Tigecycline-related pancreatitis : a review of spontaneous adverse eventreports[ J ].Pharmacotherapy ,2013,33( 1 ) : 63-68.
  • 8Steinberg WM.Acute drug and toxin induced pancreatitis[j].Hosp Pract,1985,20(5):95-102.
  • 9Elmore MF, Rogge JD.Tetracycline-induced pancreatitis [j].Gastroenterology, 1981,81(6):1134-1136.
  • 10Gotfried MH,Rodvold KA,Cwik M,et al.An open label clin-ical evaluation of tigecycline (TGC ) concentrations in se -lected tissues and fluids [J]. Clin Pharmacol Ther, 2005,77(S2):98.

共引文献38

同被引文献34

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部